| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 161 | 作爲殺真菌劑之金屬酶抑制劑化合物（一） | TW104111924 | 2015-04-14 | TW201542090A | 2015-11-16 | 洛索 麥可R; LOSO, MICHAEL R.; 蓋斯塔佛森 葛瑞D; GUSTAFSON, GARY D.; 久保田朝子; KUBOTA, ASAKO; 葉普 毛里斯C; YAP, MAURICE C.; 布宣恩 札克里A; BUCHAN, ZACHARY A.; 史戴華 金伯利M; STEWARD, KIMBERLY M.; 蕭倫伯格 麥可T; SULLENBERGER, MICHAEL T.; 虎克斯特拉 威廉J; HOEKSTRA, WILLIAM J.; 葉茲 克里斯托福M; YATES, CHRISTOPHER M. |
| 本發明描述具有金屬酶調節活性之具化學式I之化合物，及治療藉由此等金屬酶調節之其疾病、異常或症狀之方法。 | ||||||
| 162 | COMBINATIONS OF PI3K INHIBITORS WITH A SECOND ANTI -TUMOR AGENT | PCT/GB2011/051998 | 2011-10-14 | WO2012052745A1 | 2012-04-26 | PASTOR FERNÁNDEZ, Joaquín; MARTÍNEZ GONZÁLEZ, Sonia; OYARZABAL SANTAMARINA, Julen |
There is provided combinations comprising (A) a compound of formula (I), wherein R1, R2, R3, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, together with (B) one or more therapeutics agents/treatments known to be useful in the treatment of diseases such as cancer or a proliferative disease, which combinations are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease. |
||||||
| 163 | NEW COMBINATIONS OF AN ANTI EMETIC AGENT AND AN ENKEPHALINASE INHIBITOR | PCT/IB2005/000351 | 2005-02-14 | WO2005079850A1 | 2005-09-01 | SCHWARTZ, Jean-Charles; LECOMTE, Jeanne-Marie |
The present invention concerns new combinations of an anti-emetic agent and an enkephalinase inhibitor, the uses of said combinations for treating diarrhea and/or gastroenteritis. |
||||||
| 164 | USE OF GABA UPTAKE INHIBITORS AS ANTI-TUSSIVE AGENTS | PCT/US1997008948 | 1997-05-23 | WO1997043902A1 | 1997-11-27 | SMITHKLINE BEECHAM CORPORATION |
| Invented is a method of treating cough in a mammal, including a human, which comprises administering to such mammal an effective amount of an inhibitor of GABA uptake. | ||||||
| 165 | Multiplication inhibitor against dental caries fungus and pathogenic fungus of periodontal disease | JP14806991 | 1991-05-24 | JPH04346933A | 1992-12-02 | TAMAOKI YOJI; KATO TAKAYUKI; MIYAKE YOSHIAKI |
| PURPOSE: To obtain a multiplication inhibitor against dental caries fungus and pathogenic fungus of periodontal diseases, derived from a natural substance, suppressing multiplication of dental caries fungus and pathogenic fungus of periodontal diseases and preventing dental caries by adding the inhibitor to dentifrice, subduing periodontal diseases, having high safety. CONSTITUTION: Pericarp or a paricarp-containing substance of citrus fruit selected from lemon, grapefruit, naval orange, Citrus hassaku hort., satuma mandarin, kumquats, Citrus iyo hort., Citrus natsudaidai, sour orange, etc., is extracted with an organic solvent, preferably methanol, ethanol, chloroform, ethyl acetate to give an extract. The extract, a treated material thereof or a hexane-soluble fraction obtained by extracting the extract with hexane and concentrating the liquid part under reduced pressure is used as an active ingredient to give a multiplication inhibitor against dental caries fungus and pathogenic fungus of periodontal diseases. COPYRIGHT: (C)1992,JPO&Japio | ||||||
| 166 | EXPRESSION IN FILAMENTOUS FUNGI OF PROTEASE INHIBITORS AND VARIANTS THEREOF | PCT/US2004/035278 | 2004-10-22 | WO2005047302A1 | 2005-05-26 | DE NOBEL, Hans; ESTELL, David, A.; LIU, Wei; POWER, Scott, D.; SCHMIDT, Brian; WANG, Huaming |
Described herein are protease inhibitors, variants thereof and methods for their production. |
||||||
| 167 | 抗真菌剤及びフケ抑制剤 | JP2012126939 | 2012-06-04 | JP5925606B2 | 2016-05-25 | 滝川 博文; 佐藤 紀子 |
| 168 | Self-propelled soil steam disinfector and weed emergence inhibitor | JP3963598 | 1998-02-04 | JPH11220959A | 1999-08-17 | ABE TAKASHI |
| PROBLEM TO BE SOLVED: To provide a self-propelled steam disinfector and weed emergence inhibitor that can disinfect soil and sterilize weed seeds in no need of installation of steam pipe and the transfer of the soil to be disinfected. SOLUTION: This self-propelled steam disinfector and weed emergence inhibitor has a steam generator 2 mounted on the self-propelled truck 1, the steam pipe 3 for delivering the steam generated in the steam generator 2, having the downward opening 4 at the top edge of the pipe 3 for jetting out the steam, and the steam cover 8 at the upper part of the steam-jetting tube 5 having the opening 4 so that the skirt part 6 of the cover 8 may come into contact with the soil surface thereby inhibiting the steam jetted out of the steam-jetting opening 4 from diffusing. Thus, the disinfection of the soil can be automatically performed, as the self-propelled truck 1 runs around. COPYRIGHT: (C)1999,JPO | ||||||
| 169 | Immune-suppressing agent for transplantation and antiallergy agent | JP25647684 | 1984-12-06 | JPS61134312A | 1986-06-21 | UMEZAWA HAMAO; TAKEUCHI TOMIO; ISHIZUKA MASAAKI; ABE FUMINORI; FUJII AKIO; NAKAMURA TERUYA |
| PURPOSE: To provide an agent for suppressing the immunity in transplantation of organs, containing spergualin or its salt as an active component, free from side effects, and effective to suppress the transplantation immune reaction such as the rejection in the transplantation of organs such as kidney, heart, endocrine organs, skin, etc. CONSTITUTION: The objective agent contains spergualin or its pharmacologically permissible salt as an active component. The compound can be used as it is, however, it is administered usually together with a vehicle or carrier in the form of a drug preparation. For an injection, it is used by mixing with a liquid carrier, preferably physiological saline water, various buffer solutions, an aqueous solution of a sugar such as mannitol or cyclitols such as sugar alcohol, inositol, etc., or glycol such as ethylene glycol. The content of the active component is preferably 1W10wt% for injection, and 5W100wt%, preferably 25W100wt% for capsule, granule or powder. COPYRIGHT: (C)1986,JPO&Japio | ||||||
| 170 | 항혈소판제와 산 억제제를 포함하는 경구 투여용 약학 조성물 | KR1020087026891 | 2007-04-04 | KR1020080112361A | 2008-12-24 | 골드스미스,마크,에이.; 바다스,엘리자베스 |
| The present disclosure provides oral dosage forms comprising an antiplatelet agent and an acid inhibitor, as well as methods of treating subjects with an antiplatelet agent and an acid inhibitor. ® KIPO & WIPO 2009 | ||||||
| 171 | 중심체 DNA를 이용한 항진균제의 탐색 방법 및 이를 이용하여 분리한 항진균제 | KR1020030051104 | 2003-07-24 | KR1020050012020A | 2005-01-31 | 윤혜주; 신승구 |
| PURPOSE: A screening method of an antifungal agent and the isolated antifungal agent using the same are provided, thereby easily screening the antifungal agent which inhibits chromosome separation in fungi to inhibit their cell division. CONSTITUTION: The screening method of an antifungal agent comprises the steps of: providing a transformed host cell containing centrosome DNA of Saccharomyces cerevisiae or DNA having a 90% homology to the same centrosome DNA, a hybrid promoter with a galactose-inducible promoter, and a lacZ reporter gene; contacting a test compound with the transformed host cell; and determining whether the transcription of the reporter gene is inhibited, wherein the host cell is Saccharomyces cerevisiae(KCTC 10481BP) or Candida glabrata. | ||||||
| 172 | THE ANTI-NEOPLASTIC AGENT ET-743 INHIBITS TRANS ACTIVATION BY SXR | PCT/US2001/025128 | 2001-08-13 | WO02014554A2 | 2002-02-21 | |
| ET-743 is a small molecular weight compound with antineoplastic activity that inhibits the ability of the nuclear receptor SXR to trans activate gene transcription from SXR regulated response elements. The nuclear receptor SXR has been identified as a receptor that activates transcription of the mdr1 gene and thus increases multidrug resistance in cells. The interaction of SXR with the mdr1 gene and ET-743 provide a set of physiological mechanisms which can be exploited to identify novel inhibitors of SXR activation and mdr1 gene transcription and thus novel agents which exhibit an antineoplastic effect against tumor cells either alone or when coadministered with another antineoplastic agent. | ||||||
| 173 | TOPICAL ANTI-ANGIOGENIC AS HAIR GROWTH INHIBITORS | PCT/US9000812 | 1990-02-20 | WO9012577A3 | 1992-03-19 | HOLLAND J MICHAEL; LAKINGS DUANE B |
| A method of inhibiting hair growth in mammals which comprises the topical administration of a composition comprising an anti-angiogenic effective amount of an angiostatic compound of formula (I). The formula (I) compound is present in an amount of at least 1 mg/ml, preferably from about 1 mg/ml to about 10 mg/ml. | ||||||
| 174 | Use of ketol-acid reductoisomerase inhibitor for treatment of fungal disease affecting crop | JP2010270135 | 2010-12-03 | JP2011093909A | 2011-05-12 | DUMAS RENAUD; LEBRUN MARC-HENRI; ZUNDEL JEAN-LUC; EFFANTIN GERALDINE; MORIN VALERIE |
| <P>PROBLEM TO BE SOLVED: To provide a method for using acetohydroxy acid isomeroreductase for treating fungal diseases affecting crops. <P>SOLUTION: The ILV5 gene which encodes ketol-acid reductoisomerase is inactivated by a fungicidal composition containing an effective amount of an inhibitor against Magnaporthe grisea ketol-acid reductoisomerase, Saccharomyces cerevisiae ketol-acid reductoisomerase and/or Neurospora crassa ketol-acid reductoisomerase, for example, dimethylphosphinoyl-2-hydroxyacetate or N-hydroxy-N-isopropyl oxamate. <P>COPYRIGHT: (C)2011,JPO&INPIT | ||||||
| 175 | 항혈소판제와 산 억제제를 포함하는 경구 투여 형태 | KR1020157021344 | 2007-04-04 | KR1020150105419A | 2015-09-16 | 골드스미스,마크,에이.; 바다스,엘리자베스 |
| 본 명세서는 항혈소판제와 산 억제제를 포함하는 경구 투여 형태 뿐만 아니라 이러한 항혈소판제와 산 억제제를 사용하여 대상체를 치료하는 방법을 제공한다. | ||||||
| 176 | COMBINATION FAAH INHIBITOR AND ANALGESIC, ANTI-INFLAMMATORY OR ANTI-PYRETIC AGENT | PCT/US2007072677 | 2007-07-02 | WO2008021625A3 | 2008-10-09 | DASSE OLIVIER |
| Pharmacological inhibition of fatty acid amide hydrolase (FTVAH) activity leads to increased levels of fatty acid amides. Esters of alkylcarbamic acids are disclosed that are inhibitors of FAAH activity. Compounds disclosed herein inhibit FAAH activity and further provide an analgesic, anti-inflammatory, or anti-pyretic agent. Described herein is a process for the preparation of esters of alkylcarbamic acid compounds, compositions that include them, and methods of use thereof. | ||||||
| 177 | 利用芝麻蛋白質水解酵素抑制劑應用於抑制真菌之製劑及製備方法 | TW096120984 | 2007-06-11 | TWI331016B | 2010-10-01 | 徐志宏; 鄭美玲 |
| 本發明係提供一種利用芝麻蛋白質水解酵素抑制劑(sesame cystatin)應用於抑制真菌之製劑，包含有一蛋白質水解酵素抑制劑及用以回溶該蛋白質水解酵素抑制劑之一溶劑，其中該蛋白質水解酵素抑制劑係由一芝麻種子萃取或是利用生物技術所純化得到，且該蛋白質水解酵素抑制劑係為該蛋白質之胺基酸全長或其N端或C端胺基酸序列，由該製劑可單獨使用，或與其他有效成份合併使用，或將該蛋白質內主導全長或N端或C端表現的基因片段於特定微生物中表達分泌，以達到或增進生物防治的效果。 | ||||||
| 178 | 利用芝麻蛋白質水解酵素抑制劑應用於抑制真菌之製劑及製備方法 | TW096120984 | 2007-06-11 | TW200847927A | 2008-12-16 | 徐志宏 SHYU, DOUGLAS JYH HORNG; 鄭美玲 |
| 本發明係提供一種利用芝麻蛋白質水解酵素抑制劑(sesame cystatin)應用於抑制真菌之製劑,包含有一蛋白質水解酵素抑制劑及用以回溶該蛋白質水解酵素抑制劑之一溶劑,其中該蛋白質水解酵素抑制劑係由一芝麻種子萃取或是利用生物技術所純化得到,且該蛋白質水解酵素抑制劑係為該蛋白質之胺基酸全長或其N端或C端胺基酸序列,由該製劑可單獨使用,或與其他有效成份合併使用,或將該蛋白質內主導全長或N端或C端表現的基因片段於特定微生物中表達分泌,以達到或增進生物防治的效果。 | ||||||
| 179 | 항구토제와 엔케팔리나제 억제제의 배합물 | KR1020067016159 | 2005-02-14 | KR1020060132691A | 2006-12-21 | 슈워츠장샤를; 르꽁뜨잔느마리 |
| The present invention concerns new combinations of an anti-emetic agent and an enkephalinase inhibitor, the uses of said combinations for treating diarrhea and/or gastroenteritis. | ||||||
| 180 | INHIBITORS OF RTT109 AS ANTI-FUNGAL AGENTS | PCT/US2012043785 | 2012-06-22 | WO2012178036A3 | 2013-04-18 | ZHANG ZHIGUO; LIMPER ANDREW H; HAN JUNHONG; ZHOU HUI; KOTTOM THEODORE J; HOOK DEREK; BERMAN JUDITH; WALTERS MICHAEL ANTHONY |
| This document relates to materials and methods for identifying chemical inhibitors of fungal targets useful for treating organisms infected with opportunistic fungal pathogens. For example, this document provides the materials and methods for identifying and optimizing chemical inhibitors of Rtt109, a fungal histone acetyltransferase. This document also provides the materials and methods for using high throughput screening technologies to identify candidate chemical inhibitors of Rtt109 as well as the materials and methods for evaluating candidate chemical inhibitors of Rtt109 in secondary screens for their binding efficacy, molecular specificity, and cellular toxicity. | ||||||
QQ群二维码
意见反馈
意见反馈